Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE-TIMI 56: Clopidogrel Dosing by Genotype
NCT01235351Phase 2Completed
- Sponsor
- TIMI Study Group
- Start
- Oct 2010
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clopidogrel in myocardial infarction (MI) and percutaneous coronary intervention (PCI) (2 arms), sponsored by TIMI Study Group. Primary endpoint: Vasodilator-stimulated Phosphoprotein Phosphorylation Platelet Reactivity Index at 8 weeks. Started Oct 2010; status: completed.
02
Drugs
clopidogrel
03
Conditions
myocardial infarction (MI)percutaneous coronary intervention (PCI)
Beyond the preview
Go deeper on NCT01235351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01235351.